Welcome to our dedicated page for Gelteq news (Ticker: GELS), a resource for investors and traders seeking the latest updates and insights on Gelteq stock.
Gelteq Limited develops gel-based oral delivery systems for prescription drugs, nutraceuticals, pet care, sports, over-the-counter and other product categories. The company focuses on edible gel dosage formats and proprietary formulations designed for oral delivery, including white-label manufacturing and out-licensing of its technology to commercial partners.
GELS news commonly covers preclinical bioavailability and absorption studies, applications for water-soluble, oil-soluble and poorly soluble compounds, and medicinal cannabinoid delivery through the company’s oral gel platform. Updates also include nutraceutical product commercialization, distribution arrangements, sports-performance formulations, manufacturing partnerships and international market expansion.
Healthy Extracts (OTCQB:GELS) reported record Q1 2026 net revenue of $1.6 million, up 73% year over year, driven largely by the Gummy USA merger and broader distribution.
Gross profit rose 133% to $989,000 with 61.4% margin, net loss narrowed to $201,000, and EBITDA turned positive at $40,500. Management is targeting 2026 net revenue above $20 million, supported by a major Imaraïs Beauty manufacturing partnership and Gummy USA’s facility, which is expected to reach its $20 million annual production capacity.
Gelteq (ASX:GELS) arranged up to USD $3.5 million in strategic debt financing to fund commercialization, expand clinical trials and support revenue-generating opportunities. The facility provides $1 million at closing and a further $2.5 million subject to shareholder approval expected in June 2026.
The structure includes at least six months with no repayments, which Gelteq believes will preserve operational runway while it scales pharmaceutical and nutraceutical programs and accelerates sales execution across key markets.
Healthy Extracts (OTCQB:GELS) reported preliminary unaudited 2025 results showing net revenue up 45% to $4.5 million, driven by the Gummy USA merger, product launches, and channel expansion. Organic operations grew ~25% and subscription channels rose substantially, while management projects the new facility could reach a $20 million annual capacity in 2026.
Results are preliminary and subject to audit and revision before the company's Form 10-K filing.
Gelteq (ASX:GELS) and Healthy Extracts signed a Memorandum of Understanding on February 11, 2026 to enable U.S. manufacturing and global distribution of Gelteq’s proprietary gel-based nutraceutical formulations.
Healthy Extracts will manufacture, commercialise and distribute US-made gel products while Gelteq retains IP and provides technical transfer.
Gelteq (GELS) announced positive preclinical results on Jan 13, 2026 showing its oral gel delivery platform increased cannabidiol (CBD) absorption versus an FDA-approved oil product. Gelteq reported a greater than 22% increase in bioavailability and a higher peak exposure despite using a lower CBD concentration. The company says the platform enables precise, pre-measured dosing, faster uptake, and a non-invasive alternative to vaping.
Gelteq highlighted the Special Access Scheme (SAS) as a potential expedited pathway to earlier patient access in Australia and a stepping stone for global commercial partnerships and licensing opportunities.
Gelteq (NASDAQ:GELS) announced a partnership with the Hong Kong Flag Football Program on Dec 16, 2025 to integrate its gel-based hydration and sports performance formulations into men’s, women’s and youth national team training and competition.
The announcement cites recent regional commercial progress, including a China-focused sales agreement with Shenzhen Mana Health Management that carries minimum annual order commitments of at least USD $1.3 million. Gelteq noted prior adoption across Australia and Asia, including league-wide use on the Professional Pickleball Association’s PPA Tour Australia.
Gelteq (GELS) entered a three-year sales agreement with Shenzhen Mana Health Management to distribute Gelteq’s proprietary gel nutritional formulation across China.
The agreement includes minimum annual order volumes and Gelteq expects to derive a minimum of approximately USD $1.3 million in revenue during the three‑year term. Mana will use a multichannel network (digital plus offline retail) to promote a sugar‑lowering nutritional product and create a pathway to introduce additional Gelteq formulations in China.
Management said the deal builds on recent Asia sports product launches and aims to generate more predictable revenue and adoption of Gelteq’s gel delivery platform.
Gelteq (ASX:GELS) reported preclinical results showing its proprietary gel platform improved oral delivery of oil-soluble and poorly soluble drugs.
Key findings: a 300% increase in bioavailability within the first hour versus an existing FDA‑approved reference product and >20% higher overall absorption over 24 hours. Studies showed uniform small‑intestinal distribution, controlled GI transit, targeted release, effective absorption, and full clearance of API and gel material.
The company says the platform may reduce emulsifier needs, enhance bioavailability, and help reformulate challenging molecules across multiple therapeutic areas.
Gelteq (Nasdaq: GELS) announced that CEO Nathan Givoni will present at the Q4 Investor Summit Virtual on December 9, 2025 at 4:00 PM ET.
Mr. Givoni will discuss growth strategy, market positioning, and upcoming catalysts. He will also host one-on-one meetings with institutional and high-net-worth investors on December 10, 2025. Investors can request meeting access through the summit registration link or by contacting the conference or Gelteq investor relations at mkreps@darrowir.com. Event contact is fred@investorsummitgroup.com.
Gelteq (ASX:GELS) announced positive preclinical pharmacokinetic results on Nov 24, 2025 showing its proprietary gel formulation produced a 38–45% increase in systemic exposure (AUC) versus a leading marketed antihistamine, plus markedly higher Cmax and a comparable Tmax. The company said the test compound was water-soluble, supporting broader application of the gel platform across other water-soluble drug classes and strengthening plans to pursue an FDA approval pathway for an antihistamine and to engage pharmaceutical partners.